Interleukin 6 (IL-6) is a pleiotropic cytokine with a pivotal role in the pathophysiology of rheumatoid arthritis (
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disorder affecting about 1% of the population worldwide, most commonly middle-aged women. It is characterized by chronic inflammation of the synovium, particularly of small joints, which often leads to destruction of articular cartilage and juxta-articular bone. It is often accompanied with systemic manifestations such as anaemia, fatigue and osteoporosis.
RA pathogenesis involves complex humoral and cellular reactions including immune-complex formation, vascular reactions and infiltration of lymphocytes and monocytes into the synovium. These infiltrating cells and synoviocytes release pro-inflammatory mediators, including interleukin (IL)-6, which perpetuate inflammation and destruction through effects on other cell types in the synovium and periarticular structures (Figure 1) RA is thought to be initiated by immunity against an unknown antigen and later to a sustained inflammatory process [McInnes and Schett, 2007] . The presence of auto-antibodies such as anticyclic citrullinated peptide [Avouac et al. 2006 ] and increased C-reactive protein (CRP) level [Nielen et al. 2006 ] many years before the appearance of clinical symptoms suggest a role for dysregulation of the immune response in the pathogenesis of this disease.
In RA the cytokine network is complex with numerous cytokines present both in blood and in synovial joints. One of these is IL-6, which is a pleiotropic cytokine important in B-cell maturation and therefore the production of auto-antibodies, as well as the direct stimulation of CRP from hepatocytes, so it may play a significant role in RA pathogenesis [Rose-John et al. 2006 ]. In animal models of autoimmune diseases, IL-6 also plays a critical role in the generation of Th17 pro-inflammatory lymphocytes [Chen and O'Shea, 2008] . In patients with established RA, many of the articular and systemic manifestations could be explained by the biologic effect of IL-6. In this review we aim to look into the role of IL-6 in the pathophysiology of RA.
IL-6 structure, family and receptors IL-6 is a 26-kDa glycopeptide whose gene is found on chromosome 7. It is produced by various cell types, such as T cells, B cells, monocytes, fibroblasts, osteoblasts, keratinocytes, endothelial cells, mesangial cells and some tumour cells. IL-6 is one member of the IL-6 cytokine family which includes leukaemia inhibitory factor, ciliary neurotrophic factor, IL-11 and cardiotrophin-1. All of these cytokines require cell surface gp130 for cellular activation in addition to their respective cytokine receptors.
Previously, IL-6 has been known as hepatocyte stimulating factor, B-cell stimulatory factor 2, cytotoxic T-cell differentiation factor, B-cell differentiation factor, hybridoma/plasmacytoma growth factor, monocyte granulocyte inducer type 2 and thrombopoietin. The many names reflect the pleiotropism of IL-6 with important biologic effects on the liver, B cells, T cells, monocytes and platelets.
Unlike a number of other cytokines, IL-6 can activate cells through both membrane-bound (IL-6R) and soluble receptors (sIL-6R), thus widening the number of cell types responsive to this cytokine. Indeed, trans-signalling, where IL-6 binds to the sIL-6R, homodimerizes with glycoprotein 130 subunits and induces signal transduction, has been found to play a key role in acute and chronic inflammation [Dayer and Choy, 2010] . The key role of trans-signalling in RA has been demonstrated in a murine experimental arthritis model in which blocking IL-6 trans-signalling using a variant soluble gp130 molecule resulted in a marked clinical improvement in systemic arthritis [Nowel et al. 2009 ]. These findings support earlier data showing restoration of experimental arthritis disease activity in an IL-6 knock-out mouse model when administered with a sIL-6R-IL-6 fusion protein [Nowell et al. 2003 ]. The increase in IL-6 and sIL-6R in synovial fluid increases the risk of joint destruction in RA [Kotake et al. 1996 ].
Role of IL-6 in the pathophysiology of RA Adaptive immune response IgM and IgG rheumatoid factors along with antibodies to citrullinated peptides are characteristically increased in RA. The therapeutic efficacy of B-cell depletion in RA demonstrates the impact of B-cell activity on synovial inflammation and joint damage. IL-6 stimulates B cells to differentiate into plasma cells to produce immunoglobulins [Muraguchi et al. 1988 ]. IL-6 induces B-cell differentiation [Jogo et al. 2001] and has been shown to induce B-cell antibody production [Dienz et al. 2009 ]. IL-6 influences T-cell development by stimulating the proliferation and differentiation of T lymphocytes into TH-17 cells which produce IL-17. In murine models of autoimmune diseases in the presence of IL-6 and transforming growth factor beta (TGF-b), naïve T cells develop into Th17 cells. In humans this pathway is driven by IL-6 in combination with IL-1b and IL-23 rather than TGF-b [Chizzolini et al. 2008; Acosta-Rodriguez et al. 2007; Rose-John et al. 2006 ]. All of this would suggest that IL-6 has an important role in the development of the adaptive immune response and may be involved in the pathogenesis of RA.
The role of IL-6 in the shift from acute to chronic inflammation Neutrophil migration from blood to tissue is a characteristic feature of inflammation. Upon entry, activated neutrophils release proteolytic enzymes and reactive oxygen intermediates resulting in tissue destruction and joint damage in RA. Neutrophils express membrane-bound IL-6R and are activated by IL-6. When endothelial cells were cocultured with fibroblasts isolated from the synovium of RA patients, IL-6 levels increased and neutrophils adhered to the endothelium [Lally et al. 2005 ], a pivotal step prior to the migration of neutrophils into the joint.
In vivo, IL-6-negative transgenic mice show impaired leukocyte accumulation in a subcutaneous air pouches model [Romano et al. 1997 ].
Conversely, an anti-IL-6 antibody in wild-type mice reduced leukocyte infiltration to levels observed in the IL-6 deficient mice.
IL-6 has also been implicated in the shift from acute to chronic inflammation [Kaplanski et al. 2003 ] by increase recruitment of monocytes. Neutrophils release sIL-6R as they reach the site of inflammation resulting in local recruitment of leukocytes through activation of adjacent endothelial cells and subsequent chemokine release [Lindemann et al. 2004; Hurst et al. 2001; Modur et al. 1997; Romano et al. 1997 ].
Trans-signalling via sIL-6R increases the amounts of monocyte-specific chemokines secreted by endothelial cells [Marin et al. 2001 ]. Thus, activation of endothelial cells through trans-signalling results in a shift from neutrophil to monocyte infiltration.
Role of IL-6 in the development of articular symptoms in RA In the rheumatoid synovium, IL-6 is one of the most abundantly expressed cytokines [Madhok et al. 1993 ]. Levels of IL-6 and sIL-6R in synovial fluid correlate with histological characteristics of chronic synovitis in patients with RA [Sack et al. 1993] as does sIL-6R with leukocyte infiltration [Jones et al. 2005 ]. IL-6 can also promote joint inflammation and damage through its effect on vascular endothelial growth factor (VEGF) levels in RA patients. VEGF is an important angiogenic mediator which promotes the migration and proliferation of endothelial cells, as well as inducing vascular permeability and mediating inflammation [Connolly et al. 1989; Keck et al. 1989 ]. Raised levels of VEGF correlate with disease activity in RA patients [Ballara et al. 2001 ]. IL-6 in the presence of sIL-6R increased VEGF levels in cultured synovial fibroblasts from RA patients and anti-IL-6R antibody significantly reduced VEGF concentration [Nakahara et al. 2003 ].
IL-6 and joint erosions
Erosions and joint space narrowing indicate destruction of bone and articular cartilage in RA. Osteoclasts are key cells involved in mediating erosions in inflammatory arthritis [Walsh et al. 2005 ]. IL-6 increases osteoclast recruitment by acting on hematopoietic stem cells from the granulocyte-macrophage lineage [Yoshitake et al. 2008; Liu et al. 2005; Otsuka et al. 1991] . The resorptive effects of IL-6 and their regulation of receptor activator of NF-kB ligand (RANKL), receptor activator of NF-kB (RANK), and osteoprotegerin (OPG) were studied in neonatal mouse calvaria where IL-6 in the presence of sIL-6R enhanced the expression of RANKL and OPG, but decreased RANK expression and induced bone resorption, which was decreased by osteoclast inhibitors, suggesting that sIL-6R trans-signalling influences osteoclastogenesis [Palmqvist et al. 2002] . In antigen-induced arthritis (AIA) IL-6 deficient mice had reduced severity of arthritis and fewer osteoclasts at sites of bone erosion along with lower IL-17 levels compared with wild-type mice [Wong et al. 2006 ]. In RA IL-6 and sIL-6R stimulated osteoclast-like cell formation, at the concentrations found within the synovial fluid of RA patients, which was inhibited by adding anti-IL-6R antibody [Kotake et al. 1996 ].
IL-6 is also implicated in damage to the articular cartilage in RA as sIL-6R and IL-6 markedly inhibit proteoglycan synthesis in cultures of human articular chondrocytes from patients with RA [Guerne et al. 1999] .
The role of IL-6 in extracellular matrix turnover Proteinases such as matrix metalloproteinases (MMPs) in RA are produced by synovial lining cells, sublining fibroblasts and infiltrating leukocytes and macrophages [Murphy and Nagase, 2008; Yamanishi et al. 2002; Takizawa et al. 2000; Yamanaka et al. 2000; Ahrens et al. 1996; Hembry et al. 1995; Okada et al. 1990 Okada et al. , 1989 ] and target the extracellular matrix. There is a correlation between articular cartilage destruction and the expression of MMPs [Ohta et al. 1998; Imai et al. 1997; Okada et al. 1992] . Cells lining the rheumatoid synovium have been shown to overproduce MMPs whose levels are higher in RA patients than controls [Chang et al. 2008; Yamanaka et al. 2000; Ahrens et al. 1996; Hauptmann et al. 1991; Seckinger et al. 1990; Okada et al. 1990 Okada et al. , 1989 In patients with early RA, IL-6 and CRP correlate with proMMP-3 [Roux-Lombard et al. 2001 ] suggesting a link between proteinase activity and IL-6. Tissue inhibitors of matrix metalloproteinases (TIMPs) are endogenous inhibitors of MMPs. IL-6 in the presence of sIL-6R-induced TIMP-1 mRNA and protein expression in cultured human chondrocytes and synovial fibroblasts [Silacci et al. 1998 ].
IL-6 in the development of systemic symptoms of RA

Acute-phase response
During an acute-phase response there is release of pro-inflammatory cytokines and alterations in the level of acute-phase proteins in the plasma [Castell et al. 1989; Gauldie et al. 1987] . IL-6 is a principal stimulator of acute-phase protein synthesis through hepatocyte stimulation. In patients with RA, serum IL-6 levels correlate with CRP levels [Madhok et al. 1993 ].
Anaemia of chronic inflammation
Anaemia of chronic inflammation is present in more than a third of RA patients and in a quarter of patients within the first year of disease [Nikolaisen et al. 2008; Han et al. 2007 ]. Anaemia is an independent factor contributing to physical disability in patients with RA [Han et al. 2007 ].
The peptide hepcidin produced by hepatocytes regulates iron metabolism by preventing iron transport and the release of iron from macrophages [Ganz, 2003] . IL-6 stimulation induced hepcidin expression has been noted in in vitro studies of human hepatoma cells [Nemeth et al. 2004] . Turpentine stimulation of the inflammatory response in wild-type mice resulted in marked increases in liver hepcidin expression accompanied by a decrease in serum iron; however, in IL-6 knock-out mice, hepcidin levels were low and iron levels increased slightly [Nemeth et al. 2004 ]. This along with the observation that a rapid increase in hepcidin secretion occurs following IL-6 infusion in healthy volunteers suggests an important role of IL-6 in the anaemia of inflammation observed in many patients with RA.
Systemic osteoporosis
An imbalance between osteoblasts and osteoclasts results in dysregulation of bone remodelling resulting in osteoporosis. Osteoporosis is a common systemic manifestation of RA. In vivo studies with IL-6 transgenic mice showed increased osteoclastogenesis with reduced osteoblast activity resulting in accelerated bone resorption, reduced bone formation and defective ossification [De et al. 2006 ] suggesting that IL-6 overexpression results in osteopenia due to osteoclast and osteoblast dysregulation.
Fatigue and the hypothalmicpituitaryadrenal axis
Fatigue is a commonly reported problem in RA, with 41% of patients experiencing clinically important levels of fatigue [Kirwan and Hewlett, 2007; Tubach et al. 2007; Wolfe et al. 1996 ]. The cause of fatigue in RA is unknown. Pain, cytokines, hormonal, psychological, metabolic factors, and medication may all contribute. Hypothalmicpituitaryadrenal (HPA) axis abnormality has been linked to the development of fatigue in many diseases [Tsigos and Chrousos, 2002] . Cytokines such as IL-6 can modulate the HPA axis [Chrousos, 1995] . Indeed, following IL-6 administration, healthy volunteers recorded increased fatigue, inactivity, lack of concentration and altered sleep architecture. These effects were found to correspond with the HPA axis function [Spath-Schwalbe et al. 1998 ].
IL-6, lipids and inflammation
Cardiovascular mortality is increased in patients with RA. Systemic inflammation causes atherogenesis via endothelial dysfunction and dyslipidemia [van Leuven et al. 2008; Dessein et al. 2007; Niessner et al. 2007] . Elevated CRP levels are associated with an increased risk of cardiovascular disease [Yeh, 2004] . Inflammation through the effects of IL-6 reduces circulating lipid levels although mechanisms by which IL-6 induces these changes is not known [Papanicolaou et al. 1998 ]. IL-6 has been shown to affect lipid metabolism by stimulating hepatic fatty-acid synthesis and adipose-tissue lipolysis. IL-6 also increases cholesterol synthesis while decreasing cholesterol secretion [Khovidhunkit et al. 2004; Nonogaki et al. 1995] . IL-6 and CRP have been associated with increased cardiovascular risk in apparently normal healthy males [Ridker et al. 2000 ] and females [Ridker and Cook, 2004] independent of their effects on lipids. IL-6 is associated with increased mortality in patients with acute coronary syndromes [Biasucci et al. 1999] . The above would implicate IL-6 in the development of coronary artery disease. A summary of the systemic effects of IL-6 is shown in Figure 2 .
IL-6 blockade is an effective treatment in animal models
Studies in IL-6 deficient mice have shown evidence that IL-6 is essential in the development of RA [Boe et al. 1999] . Characteristically, wildtype animals developed joint inflammation and swelling about 9 days after intra-articular injection of antigen. However, IL-6 knockout mice were resistant to AIA in that no inflammatory response or synovial inflammation was induced. Subcutaneous injections of IL-6 could induce arthritis in knockout animals. In DBA/1J mice, immunization with bovine type II collagen leads to an inflammatory arthritis resembling RA clinically and histologically. Monoclonal antibody to IL-6R reduced the disease severity if given early in the disease process [Takagi et al. 1998 ]. In a primate model of RA, immunization with bovine type II collagen induces inflammatory arthritis in cynomolgus monkeys. Blocking IL-6 with anti-IL-6R monoclonal antibody led to disease improvement [Mihara et al. 2001 ].
IL-6 blockade is effective in RA
A humanized anti-IL-6R monoclonal antibody, tocilizumab (TCZ), entered into clinical trials following the successful use of anti-IL-6R antibodies in animal models of arthritis. The first clinical trial of TCZ was conducted in patients with established RA [Choy et al. 2002] . A total of 45 patients who had failed at least one diseasemodifying antirheumatic drug (DMARD) were randomized to receive a single intravenous infusion of TCZ of 0.1, 1, 5, 10 mg/kg or placebo. Patients in the 5 and 10 mg/kg arms showed rapidly improvement in disease activity by week 1 that was statistically significant when compared with placebo-treated patients. Improvement was maintained until week 8. CRP normalized after treatment in the 5 and 10 mg/kg treated patients confirming IL-6 as the dominant cytokine in generating the acute-phase response in patients with RA. A double-blind, placebo-controlled trial in 164 RA patients demonstrated that the clinical response was maintained with repeated dosing of TCZ monotherapy [Nishimoto et al. 2004] . CHARISMA, a European study, examined not only the therapeutic effect of TCZ monotherapy in RA but also its efficacy when combined with methotrexate (MTX). The study recruited 359 RA patients with partial response to MTX. It was found that TCZ was efficacious as monotherapy or in combination with MTX although the latter appeared to enhance the benefit of TCZ [Maini et al. 2006 ]. Two phase III randomized placebo control trials confirmed the therapeutic benefit of TCZ in combination with MTX [Smolen et al. 2008] or DMARDs [Genovese et al. 2008] in RA, as compared, respectively, with placebo plus MTX and placebo plus DMARDs. In combination with MTX, TCZ has also been shown to be effective in patients with RA who were refractory to tumour necrosis factor (TNF) antagonists [Emery et al. 2008 ]. TCZ monotherapy [Nishimoto et al. 2007] or in combination with MTX [Fleischmann et al. 2009 ] has been shown to reduce radiographic joint damage in RA patients. Two-year data from the LITHE study show that giving the TCZ to patients who do not adequately respond to MTX results in sustained improvement in physical function and reduced radiographic joint damage [Fleischmann et al. 2009 ].
Risk of IL-6 blockade
Infection
In the controlled studies the rate of all infections reported with TCZ 8 mg/kg plus DMARD treatment was 127 events per 100 patient years compared with 112 events per 100 patient years in the placebo plus DMARD group. In controlled clinical studies, the rate of serious infections with TCZ 8 mg/kg plus DMARDs was 5.3 events per 100 patient years exposure compared with 3.9 events per 100 patient years exposure in the placebo plus DMARD group. In the monotherapy study the rate of serious infections was 3.6 events per 100 patient years of exposure in the TCZ group and 1.5 events per 100 patient years of exposure in the MTX group. In the long-term safety population (core and extension studies), the rate of serious infections observed with TCZ plus DMARD treatment was 3.9 events per 100 patient years exposure. Reported serious infections included pneumonia, cellulitis, herpes zoster, gastroenteritis, diverticulitis, sepsis and bacterial arthritis. Serious infections were rarely fatal. Screening for latent tuberculosis (TB) is recommended prior to starting therapy with initiation of standard antimycobacterial therapy for those patients with latent TB.
Increase liver transaminases
Transient or intermittent mild and moderate elevations of hepatic transaminases have been reported particularly when TCZ is used along with MTX. Caution should be exercised when considering initiation of TCZ treatment in patients with elevated alanine transaminase (ALT) or aspartate transaminase (AST) >1.5 x ULN (upper limit of normal). In patients with baseline ALT or AST >5 x ULN, treatment is not recommended.
Decrease in neutrophils
Decreases in neutrophil count have occurred following treatment with TCZ 8 mg/kg in combination with MTX. There may be an increased risk of neutropenia in patients who have previously been treated with a TNF antagonist.
Increase in lipids
In clinical trials increases in lipid parameters have been reported with 24% experiencing sustained elevation in total cholesterol >6.2 mmol/l and 15% experiencing a sustained increase in LDL to >4.1 mmol/l which responded to treatment with lipid lowering agents.
Summary IL-6 is a pleiotropic cytokine with a pivotal role in the pathophysiology of RA. It is found in abundance in the synovial fluid and serum of patients with RA and the levels correlate with the disease activity and joint destruction. At the joint, IL-6 has a pivotal role in the inflammatory process, in osteoclast-mediated bone resorption and in pannus development through increased VEGF expression. IL-6 is pro-inflammatory, induces acute-phase proteins (including CRP) and contributes to the systemic manifestations of RA through hepcidin production (anaemia), its action on the HPA axis (fatigue) and its impact on bone metabolism (osteoporosis). In addition, IL-6 may contribute to the induction and maintenance of the autoimmune process through B-cell modulation and TH-17 differentiation. All of the above makes IL-6 blockade a desirable option in the treatment of RA. Following successful animal studies a humanized anti-IL-6R monoclonal antibody, TCZ, entered into clinical trials and it has shown to be an effective choice in the long-term management of RA with rapid and sustained improvement in disease activity, reducing radiographic joint damage and improving physical function in patients with RA.
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